Loading grant details…
Completed
RESEARCH
Europe PMC
Zanubrutinib for waldenstrom's macroglobulinaemia [ID1427]
£656.3K
GBP
| Funder | National Institute for Health Research |
|---|---|
| Recipient Organization | Kleijnen Systematic Reviews Ltd |
| Country | United Kingdom |
| Start Date | Mar 16, 2021 |
| End Date | Apr 12, 2022 |
| Duration | 392 days |
| Number of Grantees | 1 |
| Roles | Award Holder |
| Data Source | Europe PMC |
| Grant ID | NIHR133529 |
Grant Description
To appraise the clinical and cost effectiveness of zanubrutinib within its marketing authorisation for treating Waldenström’s macroglobulinaemia.
All Grantees
Kleijnen Systematic Reviews Ltd
Advertisement
Advertisement
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Start Year
2021
End Year
2022
Grantees
1
Related Grants
Lassa Fever Vaccine Efficacy And Prevention for West Africa...
European & Developing Countries Clinical...
€2.29M EUR
Platform Adaptive trial of NOvel antiviRals for eArly treatM...
National Institute for Health and Care R...
£2.14M GBP
The Swedish contribution to the construction and operation o...
Swedish Research Council
1.95M kr SEK
Advertisement
